Inhibition of JAK2 and MDM2 to treat secondary acute myeloid leukemia evolving from myelofibrosis

Inhibition of JAK2 and MDM2 to treat secondary acute myeloid leukemia evolving from myelofibrosis

Abstract Myelofibrosis (MF) is characterized by splenomegaly, extramedullary hematopoiesis, bone marrow fibrosis, anemia, constitutional symptoms, and risk of secondary acute myeloid leukemia (sAML). The prognosis for sAML is very poor, with a median survival of less than 6 months, largely due to it...

Full description

Saved in:
Bibliographic Details
Main Authors: Fuping Wang, Longxin Chen, Limeng Zhang, Siyu Du, Yingying Feng
Format: Article
Language:English
Published: SpringerOpen 2024-12-01
Series:Egyptian Journal of Medical Human Genetics
Subjects:
Secondary acute myeloid leukemia
Myelofibrosis
JAK2
P53
Targeted therapies
Online Access:https://doi.org/10.1186/s43042-024-00616-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items